MO Altria Group Inc

FDA to Begin Substantive Review of on!® Nicotine Pouches

Altria Client Services today announced that the Food and Drug Administration (FDA) has accepted and filed for substantive review premarket tobacco product applications for 35 on!® products manufactured by Helix Innovations LLC, an Altria joint venture responsible for the global on!® nicotine pouch product portfolio.

To support these applications, Altria submitted over 66,000 pages of documentation, including six primary studies.

“We believe the scientific evidence in these applications demonstrates that the marketing of on!® is appropriate for the protection of public health,” said Paige Magness, Senior Vice President, Regulatory Affairs for Altria Client Services. “on!® nicotine pouches are a key part of our vision to responsibly lead the transition of adult smokers to a non-combustible future.”

FDA will now undertake a substantive scientific review of the applications.

on!® nicotine pouches are tobacco leaf-free and are available in seven flavors and five nicotine levels. In the fast-growing nicotine pouch category, on! ® currently offers the broadest portfolio of choices for adult tobacco consumers seeking alternatives to traditional tobacco products.

on! ® was distributed in over 28,000 stores at the end of the first quarter, including the top five convenience store chains by volume. According to IRI, total oral tobacco derived nicotine category sales in 2019 grew approximately 275% compared to 2018.

Altria’s Profile

Altria’s wholly owned subsidiaries include Philip Morris USA Inc. (PM USA), U.S. Smokeless Tobacco Company LLC (USSTC), John Middleton Co. (Middleton), Sherman Group Holdings, LLC and its subsidiaries (Nat Sherman), Ste. Michelle Wine Estates Ltd. (Ste. Michelle) and Philip Morris Capital Corporation (PMCC). Altria owns an 80% interest in Helix Innovations LLC (Helix). Altria holds equity investments in Anheuser-Busch InBev SA/NV (ABI), JUUL Labs, Inc. (JUUL) and Cronos Group Inc. (Cronos).

The brand portfolios of Altria’s tobacco operating companies include Marlboro®, Black & Mild®, Copenhagen®, Skoal® and on!®. Ste. Michelle produces and markets premium wines sold under various labels, including Chateau Ste. Michelle®, 14 Hands® and Stag’s Leap Wine Cellars, and it imports and markets Antinori®, Champagne Nicolas Feuillatteand Villa Maria Estate products in the United States. Trademarks and service marks related to Altria referenced in this release are the property of Altria or its subsidiaries or are used with permission.

More information about Altria is available at altria.com and on the Altria Investor app, or follow Altria on Twitter, Facebook and LinkedIn.

EN
09/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Altria Group Inc

Altria Group Inc. - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Moody's Ratings assigns A3 to Altria's new notes; outlook remains stab...

Moody's Ratings (Moody's) assigned A3 ratings to Altria Group Inc.'s ("Altria") new US dollar backed senior unsecured long term notes issued in multiple tranches. All other ratings for the company including the A3 senior unsecured, Prime-2 commercial paper, and (P)A3 medium-term note program remain ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Gap Supports Holding; Expecting Test of All-Time Highs We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass). We will maintain our bullish view as long as market dynamics remain healthy and the S&P 500 (SPX) is above 5500. Our base case expectation is that SPX holds above short-term gap support at 5700-5785 (which is also where the 20-day, 100-day, and 200-day MAs all converge). However, if 5700 does break (a...

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: June 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ResearchPool Subscriptions

Get the most out of your insights

Get in touch